Tevogen Bio Holdings Inc (TVGN) Stock Price, Quote & News

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pati...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 838 6436

Website: tevogen.com

Address:

15 Independence Boulevard, Suite #410, Warren, United States

emilpepemil Mar. 20 at 6:17 AM

$TVGN ...no risk..no fun! 😉 Upcoming Q4 2025 Forecast Analysts have projected the following for the next report: Estimated EPS: -$1.50. Revenue Estimate: $0.00. Fiscal Year End: December 31. TradingView TradingView +2 Strategic & Market Updates Capital Position: As of late 2024, the company reported sufficient capital to fund operations for 33 months and significantly reduced its liabilities from $99.9 million to $10.5 million. Reverse Stock Split: A reverse stock split was announced on March 4, 2026, which may introduce near-term trading volatility and is done (1:50) Revenue Target: Management anticipates reaching initial revenue by the end of 2026. Recent Activity: The company recently signed letters of intent to evaluate the acquisition of Apozeal Pharmaceutical and a contract research organization (CRO). Tevogen Tevogen +5

0 · Reply

emilpepemil Mar. 20 at 6:05 AM

$TVGN Next Steps and Partnership Strategy As predictive accuracy continues to improve, Tevogen intends to explore partnerships with pharmaceutical companies to advance select peptide candidates for production and development. Mittul Mehta, CIO & Head of Tevogen.AI, stated, "Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value." https://www.nasdaq.com/press-release/tevogen-advances-generics-strategy-signs-letter-intent-evaluate-potential-acquisition

0 · Reply

emilpepemil Mar. 20 at 5:57 AM

$TVGN ...really exciting...maybe i will buy some shares...lowfloater...needs volume... 🤔🚀😎 These results allow the model to improve in identifying which immune targets are likely to succeed. The current version, trained on 1.8 million data points, is nearly 20 times more robust than the initial model, reflecting rapid scale and learning acceleration. Drug development today relies heavily on trial-and-error, and by improving target prediction before clinical testing, Tevogen aims to: Reduce time to market Lower development costs Increase probability of clinical success Extend the value of patent-protected products This development builds on Tevogen.AI's published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases.

0 · Reply

NGCS Mar. 19 at 8:57 PM

$TVGN today was 10th day over 1 usd/share of NASDAQ compliance. Now it is time to go up based on key katalysts.

2 · Reply

mark31 Mar. 18 at 7:41 PM

$TVGN

0 · Reply

ACInvestorBlog Mar. 18 at 4:52 PM

$TVGN watch the volume here. Stock is extremely oversold while MACD Hist is curling up. Tiny float AI small bio name Tomorrow Microsoft Fabric Community Conference (FabCon 2026 - Press release

0 · Reply

NGCS Mar. 17 at 11:03 PM

$TVGN To summ up (IMO), today´s Market Situation: The market is currently valuing the combination of Tevogen + Sciometrix + Apozeal as a comprehensive biotechnological "holding" company: - Tevogen: The science (T-Cells). - Sciometrix: Data and patients (AI/Clinicus). - Apozeal: Manufacturing and immediate revenue (Generics). My verdict: Apozeal serves as the guarantee that Tevogen has a tangible business in place while awaiting FDA approvals. The official announcement of the definitive merger with Apozeal could be the catalyst that drives the stock from its current $5.43 into the $8.00 - $10.00 range next week.

0 · Reply

NGCS Mar. 17 at 10:59 PM

$TVGN ...some more information from Social Network (same than before, NFA): 2. Federal Financing (U.S.) BARDA and NIH: Given that TVGN-489 addresses COVID-19 and Long COVID (both considered national health priorities), Tevogen has been engaged in discussions and application processes for contracts with the Biomedical Advanced Research and Development Authority (BARDA). These contracts often involve hundreds of millions of dollars and do not require repayment or the issuance of shares. 3. The "Apozeal" Factor The link with Apozeal and the Patel family serves as a financial safety net. While technically structured as loans or investments, these are often framed as "strategic partner support" with terms significantly more favorable than standard bank credit, allowing the company to continue operations without depleting its cash reserves.

0 · Reply

NGCS Mar. 17 at 10:57 PM

$TVGN Tevogen Bio (TVGN) is actively managing the receipt of public grants and funds that do not involve shareholder dilution. As of March 2026, these are the primary non-dilutive financing avenues currently open to the company: 1. State Grants New Jersey State Funds: Tevogen has already been a beneficiary of programs from the New Jersey Economic Development Authority (NJEDA). In early 2025, they secured up to $10 million in grant funding, with initial tranches already received. R&D Tax Credits: The company regularly utilizes New Jersey’s NOL (Net Operating Loss) Tax Benefit Transfer Program, which allows them to sell their tax losses to profitable companies in exchange for immediate cash to fund their laboratory operations. 2. Federal Financing (U.S.) ... next post.

0 · Reply

NGCS Mar. 17 at 10:46 PM

$TVGN IMO, Key Catalysts (Q1-Q2 2026): - Revenue Generation: Anticipated definitive closing of the Sciometrix acquisition before the April 2 earnings call. This marks the shift to immediate recurring revenue via digital patient management for Long COVID. - Potential Institutional Entry: Breaking the $5.00 psychological barrier removes "penny stock" restrictions for many institutional funds, potentially leading to increased "Smart Money" accumulation. - Tevogen.AI + Clinicus: Synergy between AI-driven T-cell therapy and real-world patient data (Sciometrix) accelerates clinical timelines and reduces R&D burn rate. - Investor Outlook: The risk of delisting is low enough (today is 8th day of 10 days NASDAQ compliance). The focus now shifts to execution. If the Sciometrix deal closes by late March, $5.43 could become the new support floor, with analysts targeting $12.00 - $15.00 as the next resistance levels.

0 · Reply

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Mar 13, 2026, 2:45 PM EDT - 8 days ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Mar 13, 2026, 12:30 PM EDT - 8 days ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Mar 11, 2026, 3:15 PM EDT - 10 days ago

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Mar 9, 2026, 7:45 AM EDT - 12 days ago

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Mar 6, 2026, 3:40 PM EST - 15 days ago

Letter to Shareholders from CEO Dr. Ryan Saadi

Mar 6, 2026, 12:42 PM EST - 15 days ago

Tevogen Bio Explores Buyout To Boost Generics Platform

Mar 5, 2026, 2:50 PM EST - 16 days ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Mar 4, 2026, 8:00 AM EST - 17 days ago

Tevogen Announces Reverse Stock Split

Feb 27, 2026, 2:20 PM EST - 22 days ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Feb 26, 2026, 4:22 PM EST - 23 days ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 9:20 AM EST - 23 days ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Jan 30, 2026, 3:00 PM EST - 7 weeks ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 29, 2026, 2:45 PM EST - 7 weeks ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Jan 12, 2026, 9:00 AM EST - 2 months ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Dec 22, 2025, 12:40 PM EST - 3 months ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 19, 2025, 11:10 AM EST - 3 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 11, 2025, 3:15 PM EST - 3 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 9, 2025, 2:20 PM EST - 3 months ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 8, 2025, 2:50 PM EST - 3 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Nov 14, 2025, 2:32 PM EST - 4 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Nov 5, 2025, 3:20 PM EST - 4 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 3, 2025, 2:45 PM EST - 4 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Oct 29, 2025, 12:35 PM EDT - 5 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Oct 15, 2025, 3:50 PM EDT - 5 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Sep 25, 2025, 8:30 AM EDT - 6 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 23, 2025, 8:30 AM EDT - 6 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 19, 2025, 3:40 PM EDT - 6 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 10, 2025, 11:59 AM EDT - 6 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 9, 2025, 3:15 PM EDT - 6 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 8, 2025, 9:27 AM EDT - 6 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 4, 2025, 3:48 PM EDT - 7 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 3, 2025, 4:15 PM EDT - 7 months ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Aug 27, 2025, 3:20 PM EDT - 7 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 26, 2025, 2:50 PM EDT - 7 months ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 25, 2025, 3:10 PM EDT - 7 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 22, 2025, 3:25 PM EDT - 7 months ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 19, 2025, 3:40 PM EDT - 7 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 12:10 PM EDT - 7 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 18, 2025, 5:50 PM EDT - 7 months ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:15 PM EDT - 7 months ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 14, 2025, 3:55 PM EDT - 7 months ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 13, 2025, 3:53 PM EDT - 7 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 11, 2025, 3:45 PM EDT - 7 months ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 1:24 PM EDT - 7 months ago

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Aug 11, 2025, 11:58 AM EDT - 7 months ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Aug 11, 2025, 9:28 AM EDT - 7 months ago

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 8, 2025, 11:37 AM EDT - 8 months ago

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 7, 2025, 9:00 AM EDT - 8 months ago

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Aug 6, 2025, 3:59 PM EDT - 8 months ago

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

emilpepemil Mar. 20 at 6:17 AM

0 · Reply

emilpepemil Mar. 20 at 6:05 AM

0 · Reply

emilpepemil Mar. 20 at 5:57 AM

0 · Reply

NGCS Mar. 19 at 8:57 PM

$TVGN today was 10th day over 1 usd/share of NASDAQ compliance. Now it is time to go up based on key katalysts.

2 · Reply

mark31 Mar. 18 at 7:41 PM

$TVGN

0 · Reply

ACInvestorBlog Mar. 18 at 4:52 PM

$TVGN watch the volume here. Stock is extremely oversold while MACD Hist is curling up. Tiny float AI small bio name Tomorrow Microsoft Fabric Community Conference (FabCon 2026 - Press release

0 · Reply

NGCS Mar. 17 at 11:03 PM

0 · Reply

NGCS Mar. 17 at 10:59 PM

0 · Reply

NGCS Mar. 17 at 10:57 PM

0 · Reply

NGCS Mar. 17 at 10:46 PM

0 · Reply

NGCS Mar. 17 at 10:43 PM

$TVGN My DD (NFA, do yours), TVGN Executive Summary; The Post-Split Turnaround. Current Status (As of March 17, 2026): - Nasdaq Compliance: Day 8 of 10 completed. Successfully maintaining price well above the $1.00 requirement (currently trading at $5.43 post-market). Official compliance expected by Friday, March 20. - Share Structure: Following the 1:50 reverse split, the float has significantly tightened, creating a strong setup for a potential Short Squeeze as shorts cover before official compliance. - Strategic Pivot: Moving from a pure clinical-stage biotech to a revenue-generating HealthTech firm through the integration of Sciometrix (Clinicus platform) and Apozeal Pharmaceutical.

0 · Reply